Hydrophobic Drug Delivery remains one of the most persistent challenges in modern pharmaceutical development. Many promising therapeutic molecules such as macrolides, cyclic peptides, linear peptides, and polyketides demonstrate strong bioactivity, but their poor aqueous solubility creates obstacles for systemic administration.

These molecules often fail to progress through clinical development because they cannot be formulated effectively for intravenous use. Sapu Nano’s Deciparticle platform introduces a novel approach that may help solve this problem by consistently producing sub-20 nm nanoparticles suitable for intravenous delivery.

This capability may help recover previously abandoned drug candidates and support more predictable absorption, controlled release, and improved safety outcomes.

NX210c is emerging as one of the more scientifically grounded preclinical candidates in spinal cord injury research. Spinal cord injury, often referred to as SCI, remains a devastating neurological condition that affects hundreds of thousands of people worldwide every year.

Patients frequently experience permanent motor, sensory, and autonomic deficits below the site of injury. Despite decades of intensive research, pharmacological therapies that reliably restore motor function after SCI remain limited, and most treatment strategies still focus on surgical intervention, acute stabilization, and long-term rehabilitation rather than true neurological repair.

Against this backdrop, NX210c has attracted attention for its multi-dimensional effects in animal models of SCI. Derived from thrombospondin-related biology, NX210c has demonstrated improvements in motor function, tissue preservation, and neuronal signaling in preclinical studies.